The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignancies
Bahram Valamehr, PhD, Fate Therapeutics Inc., San Diego, CA, discusses the multi-antigen targeted CAR-iNK (iPSC derived natural killer) cell immunotherapy for B-cell malignancies as a monotherapy and in combination with monoclonal antibody therapy such as rituximab, FT596. This engineered immune cell is consistently manufactured from a master iPSC line engineered to uniformly express an NK cell-calibrated CD19-targeting CAR, an enhanced functioning high-affinity, non-cleavable CD16 (hnCD16) and a recombinant fusion of IL-15 and IL-15 receptor alpha (IL-15RF) for cytokine-autonomous persistence. Studies performed demonstrated FT596 provides a multi-antigen targeting, potent and persistent engineered immune cell. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
